| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
1 company
Arch Venture Fund Xiii, L.P. is a 10% Owner at LYEL. Recent filings cover 1 purchase and 0 sales. Those positions are worth an estimated $36.5M at current prices.
Arch Venture Fund Xiii, L.P.'s largest disclosed position is in LYEL as 10% Owner, worth about $36.5M. Net of sales, the recent Form 4 record there shows accumulation of 488,090 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | LYEL Lyell Immunopharma, Inc. | 10% Owner | Buy | 488,090 | $25.61 | $12,499,984.90 | +52.0% | -41.9% | - |